Iran Press/ Iran News: The clinical trial of the 2nd phase of the 'Razi COV-Pars' nose-spray vaccine has been done in a group of 500 volunteers in Tehran.
The Razi COV-Pars vaccine is done in three doses; the first two doses were injectable, and the third is nasal.
In an interview with Iran Press on the safety of COV-Pars vaccine, the head of the Razi Vaccine and Serum Research Institute stressed that the data analysis should be carried out to be more explicit about the vaccine's safety and immunity, but the received data indicates that the vaccine safety is promising.
"Regarding its role in vaccination, after the third phase, it can be determined whether the 'COV-Pars' can be used in vaccination. The process of the third phase is underway, and of course, obtaining a license from the Food and Drug Administration is one of the steps that must be considered for nationwide vaccination usage," Head of the Razi Vaccine and Serum Research Institute Ali Es'haghi said.
No definite time can be specified to get FDA approval, but it is estimated that it takes at least two months, Es'haghi noted.
224/206
Read More:
Iran's 'Razi COV-Pars,' unique vaccine with the inhaled dose
Iran's 'Razi COV-Pars,' unique vaccine with the inhaled dose
